Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - mitozantrone hydrochloride -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases and is indicated for the treatment of:,? breast cancer,? gastric cancer,? ovarian cancer,? small cell lung cancer,? lymphoma (non-hodgkin?s lymphoma),? advanced/metastatic soft tissue sarcoma,? superficial bladder cancer (tis; ta).,in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases and is indicated for the treatment of:,? breast cancer,? gastric cancer,? ovarian cancer,? small cell lung cancer,? lymphoma (non-hodgkin?s lymphoma),? advanced/metastatic soft tissue sarcoma,? superficial bladder cancer (tis; ta).,in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases and is indicated for the treatment of:,? breast cancer,? gastric cancer,? ovarian cancer,? small cell lung cancer,? lymphoma (non-hodgkin?s lymphoma),? advanced/metastatic soft tissue sarcoma,? superficial bladder cancer (tis; ta).,in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - ondansetron hydrochloride dihydrate - solution for injection - 2mg/1ml

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - ondansetron hydrochloride dihydrate - solution for injection - 2mg/1ml

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - ondansetron hydrochloride dihydrate - solution for injection - 2mg/1ml

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - ondansetron hydrochloride dihydrate - solution for injection - 2mg/1ml

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - mitoxantrone hydrochloride - solution for infusion - 2mg/1ml

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - idarubicin hydrochloride (unii: 5vv3mdu5ie) (idarubicin - unii:zrp63d75jw) - idarubicin hydrochloride 1 mg in 1 ml - idarubicin hydrochloride injection, usp in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes french-american-british (fab) classifications m1 through m7.